The Buzz

All markets and investing news all the time

Arena surges on weight loss drug approval

June 27, 2012: 3:21 PM ET

Talk about a good weight gain. Little-known Arena Pharmaceuticals just got a big boost from the FDA, which gave its stamp of approval on the company's weight loss drug, known as Belviq.

The news sent shares of Arena (ARNA) surging 35%, giving it a year-to-date gain of a whopping 428%. Not bad for a company that not many mainstream folks have heard of. That could be good news for Vivus (VVUS), which is hoping to get its own weight loss drug approved later this month.

Obesity is a huge (no pun intended) problem and Belviq is the first prescription weight-loss drug to get FDA approval in 13 years. Abbott Labs (ABT) pulled its weight loss drug Meridia last year, at the FDA's request, due to increased risks of heart attack and stroke.

CNN.com's The Chart blog: More on FDA approval of Belviq

Fighting the obesity epidemic has been a hallmark of First Lady Michelle Obama's physical fitness campaign. And let's not forget New York City Mayor Michael Bloomberg, who pushed for banning trans fats from restaurants and most recently turned his attention to sugary drinks larger than 16 ounces.

Of course, what's good for one (or two) companies, is of course not always good for others. Shares of Weight Watchers (WTW) slid to a new 52-week low, although Nutrisystem (NTRI) managed to step higher.

Belviq is supposed to be used in conjunction with a low calorie diet and exercise program. It's also targeted toward people who have related so-called comorbid conditions like hypertension or Type 2 diabetes.

"The FDA approval of belviq is an important development for patients who struggle with obesity or are overweight with comorbidities and need help with chronic weight management beyond diet and exercise," said Arena CEO Jack Lief.

Surprisingly, or not, the list of common side effects isn't too chilling... nausea, dizziness, fatigue, headache and, of course, constipation.

Fear & Greed
Sponsored by

To view my watchlist

Not a member yet?

Sign up now for a free account
Stupid Stock Move of the Day
#StupidStock Move of the Day! $FEYE up 7% because of $SNE? Yes. It's a cybersecurity company. But has history of losses and sales misses.
Powered by WordPress.com VIP.
Follow

Get every new post delivered to your Inbox.

Join 242 other followers